MedTrace Logo

Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

NCT03456700 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-05-08

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well auranofin and sirolimus work in treating participants with ovarian cancer. Immunosuppressive therapy, such as auranofin and sirolimus, is used to decrease the body?s immune response and may increase blood cell count.

Conditions

  • Ovarian Serous Tumor
  • Recurrent Ovarian Carcinoma

Interventions

DRUG

Auranofin

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Sirolimus

Given PO

Sponsors & Collaborators

Principal Investigators

  • Aminah Jatoi, M.D. · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-30
Primary Completion
2019-07-31
Completion
2019-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03456700 on ClinicalTrials.gov